Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study

Overview

Journal J Clin Endocrinol Metab

Publisher Oxford University Press

Specialty Endocrinology

Date 2022 Jan 17

PMID 35037935

Authors

Dahlia F Davidoff

Diana E Benn

Michael Field

Ashley Crook

Bruce G Robinson

Katherine Tucker

Richard De Abreu Lourenco

John R Burgess

Roderick J Clifton-Bligh

Affiliations

Soon will be listed here.

Abstract

Context: Carriers of succinate dehydrogenase type B (SDHB) pathogenic variants (PVs) are at risk of pheochromocytoma and paraganglioma (PPGL) from a young age. It is widely recommended carriers enter a surveillance program to detect tumors, but there are limited studies addressing outcomes of surveillance protocols for SDHB PV carriers.

Objective: The purpose of this study was to describe surveillance-detected (s-d) tumors in SDHB PV carriers enrolled in a surveillance program and to compare their outcomes to probands.

Methods: This was a multicenter study of SDHB PV carriers with at least 1 surveillance episode (clinical, biochemical, imaging) in Australian genetics clinics. Data were collected by both retrospective and ongoing prospective follow-up. Median duration of follow-up was 6.0 years.

Results: 181 SDHB PV carriers (33 probands and 148 nonprobands) were assessed. Tumors were detected in 20% of nonprobands undergoing surveillance (age range 9-76 years). Estimated 10-year metastasis-free survival was 66% for probands and 84% for nonprobands with s-d tumors (P = .027). S-d tumors were smaller than those in probands (median 27 mm vs 45 mm respectively, P = .001). Tumor size ≥40 mm was associated with progression to metastatic disease (OR 16.9, 95% CI 2.3-187.9, P = .001). Patients with s-d tumors had lower mortality compared to probands: 10-year overall survival was 79% for probands and 100% for nonprobands (P = .029).

Conclusion: SDHB carriers with s-d tumors had smaller tumors, reduced risk of metastatic disease, and lower mortality than probands. Our results suggest that SDHB PV carriers should undertake surveillance to improve clinical outcomes.

Citing Articles

Management and follow-up strategies for patients with head and neck paraganglioma.

Richter S, Pacak K, Kunst H, Januszewicz A, Nolting S, Remde H Eur J Endocrinol. 2024; 191(4):389-398.

PMID: 39303070 PMC: 11443905. DOI: 10.1093/ejendo/lvae113.

International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents.

Casey R, Hendriks E, Deal C, Waguespack S, Wiegering V, Redlich A Nat Rev Endocrinol. 2024; 20(12):729-748.

PMID: 39147856 DOI: 10.1038/s41574-024-01024-5.

Identification of Succinate Dehydrogenase Gene Variant Carriers by Blood Biomarkers.

Gebhardt M, Kunath C, Frobel D, Funk A, Peitzsch M, Nolting S J Endocr Soc. 2024; 8(9):bvae142.

PMID: 39145115 PMC: 11323779. DOI: 10.1210/jendso/bvae142.

Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles.

Flynn A, Pattison A, Balachander S, Boehm E, Bowen B, Dwight T Res Sq. 2024; .

PMID: 38978571 PMC: 11230496. DOI: 10.21203/rs.3.rs-4410500/v1.

[Ga]DOTATOC PET-derived radiomics to predict genetic background of head and neck paragangliomas: a pilot investigation.

Pepponi M, Berti V, Fasciglione E, Montanini F, Canu L, Hubele F Eur J Nucl Med Mol Imaging. 2024; 51(9):2684-2694.

PMID: 38687372 DOI: 10.1007/s00259-024-06735-5.

References

van Hulsteijn L, Dekkers O, Hes F, Smit J, Corssmit E . Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet. 2012; 49(12):768-76. DOI: 10.1136/jmedgenet-2012-101192. View

Benn D, Gimenez-Roqueplo A, Reilly J, Bertherat J, Burgess J, Byth K . Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2005; 91(3):827-36. DOI: 10.1210/jc.2005-1862. View

Tufton N, Shapiro L, Srirangalingam U, Richards P, Sahdev A, Kumar A . Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. Clin Endocrinol (Oxf). 2016; 86(2):286-296. DOI: 10.1111/cen.13246. View

Amar L, Pacak K, Steichen O, Akker S, Aylwin S, Baudin E . International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol. 2021; 17(7):435-444. PMC: 8205850. DOI: 10.1038/s41574-021-00492-3. View

Rijken J, van Hulsteijn L, Dekkers O, Niemeijer N, Leemans C, Eijkelenkamp K . Increased Mortality in but Not in Pathogenic Variant Carriers. Cancers (Basel). 2019; 11(1). PMC: 6356820. DOI: 10.3390/cancers11010103. View

Tufton N, Sahdev A, Drake W, Akker S . Can subunit-specific phenotypes guide surveillance imaging decisions in asymptomatic SDH mutation carriers?. Clin Endocrinol (Oxf). 2018; 90(1):31-46. DOI: 10.1111/cen.13877. View

Jafri M, Whitworth J, Rattenberry E, Vialard L, Kilby G, Kumar A . Evaluation of SDHB, SDHD and VHL gene susceptibility testing in the assessment of individuals with non-syndromic phaeochromocytoma, paraganglioma and head and neck paraganglioma. Clin Endocrinol (Oxf). 2012; 78(6):898-906. DOI: 10.1111/cen.12074. View

Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L . Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. J Clin Endocrinol Metab. 2019; 104(6):2367-2374. DOI: 10.1210/jc.2018-01968. View

Davidoff D, Benn D, Field M, Crook A, Robinson B, Tucker K . Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study. J Clin Endocrinol Metab. 2022; 107(5):e1907-e1916. PMC: 9016424. DOI: 10.1210/clinem/dgac019. View

10.

Fishbein L, Ben-Maimon S, Keefe S, Cengel K, Pryma D, Loaiza-Bonilla A . mutation carriers with malignant pheochromocytoma respond better to CVD. Endocr Relat Cancer. 2017; 24(8):L51-L55. DOI: 10.1530/ERC-17-0086. View

11.

Greenberg S, Jacobs M, Wachtel H, Anson A, Buchmann L, Cohen D . Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma-pheochromocytoma syndrome. Genet Med. 2020; 22(12):2101-2107. PMC: 7710583. DOI: 10.1038/s41436-020-0921-3. View

12.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

13.

Dhir M, Li W, Hogg M, Bartlett D, Carty S, McCoy K . Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma. Ann Surg Oncol. 2017; 24(12):3624-3630. DOI: 10.1245/s10434-017-6074-1. View

14.

Bausch B, Wellner U, Bausch D, Schiavi F, Barontini M, Sanso G . Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer. 2013; 21(1):17-25. DOI: 10.1530/ERC-13-0415. View

15.

Imamura H, Muroya K, Tanaka E, Konomoto T, Moritake H, Sato T . Sporadic paraganglioma caused by de novo SDHB mutations in a 6-year-old girl. Eur J Pediatr. 2015; 175(1):137-41. DOI: 10.1007/s00431-015-2614-5. View

16.

Thompson M, Parameswaran V, Burgess J . Clinical utility of chromogranin A for the surveillance of succinate dehydrogenase B- and succinate dehydrogenase D-related paraganglioma. Ann Clin Biochem. 2018; 56(1):163-169. DOI: 10.1177/0004563218811865. View

17.

Timmers H, Pacak K, Huynh T, Abu-Asab M, Tsokos M, Merino M . Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab. 2008; 93(12):4826-32. PMC: 2626451. DOI: 10.1210/jc.2008-1093. View

18.

Assadipour Y, Sadowski S, Alimchandani M, Quezado M, Steinberg S, Nilubol N . SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. Surgery. 2016; 161(1):230-239. PMC: 5164946. DOI: 10.1016/j.surg.2016.05.050. View

19.

Jochmanova I, Abcede A, Guerrero R, Malong C, Wesley R, Huynh T . Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. J Cancer Res Clin Oncol. 2020; 146(4):1051-1063. PMC: 7388579. DOI: 10.1007/s00432-020-03138-5. View

20.

Jochmanova I, Wolf K, King K, Nambuba J, Wesley R, Martucci V . SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol. 2017; 143(8):1421-1435. PMC: 5505780. DOI: 10.1007/s00432-017-2397-3. View